Pharmacokinetics of first-line tuberculosis drugs in Tanzanian patients

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 7, 2013, Pages 3208-3213

  Tostmann, Alma ^a   Mtabho, Charles M ^b   Semvua, Hadija H ^b   Van Den Boogaard, Jossy ^a,b,c   Kibiki, Gibson S ^b   Boeree, Martin J ^a   Aarnoutse, Rob E ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b KILIMANJARO CHRISTIAN MEDICAL CENTRE   (Tanzania)

^c BELACD de Pala ^*  (Chad)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLISONIAZID; AMOXICILLIN; COTRIMOXAZOLE; DICLOFENAC; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; VITAMIN B COMPLEX;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; EXTRAPULMONARY TUBERCULOSIS; FEMALE; FOOD INTAKE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; LUNG TUBERCULOSIS; MALE; MAXIMUM PLASMA CONCENTRATION; PHENOTYPE; PRIORITY JOURNAL; TANZANIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME;

ADULT; ANTITUBERCULAR AGENTS; ETHAMBUTOL; FEMALE; HUMANS; ISONIAZID; MALE; PYRAZINAMIDE; RIFAMPIN; TANZANIA; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 84879023073     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02599-12     Document Type: Article

References (36)

1. Holdiness MR. 1984. Clinical pharmacokinetics of the antituberculosis drugs. Clin. Pharmacokinet. 9:511-544. (Pubitemid 15211649)
2. Peloquin CA. 1991. Antituberculosis drugs: pharmacokinetics, p 59-88. In Heifets L (ed), Drug susceptibility in the chemotherapy of mycobacterial infections. CRC Press, Boca Raton, FL.
3. Kimerling ME, Phillips P, Patterson P, Hall M, Robinson CA, Dunlap NE. 1998. Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients. Chest 113:1178-1183. (Pubitemid 28223801)
4. Mehta JB, Shantaveerapa H, Byrd RP, Jr, Morton SE, Fountain F, Roy TM. 2001. Utility of rifampin blood levels in the treatment and follow-up of active pulmonary tuberculosis in patients who were slow to respond to routine directly observed therapy. Chest 120:1520-1524. (Pubitemid 33078467)
5. Weiner M, Burman W, Vernon A, Benator D, Peloquin CA, Khan A, Weis S, King B, Shah N, Hodge T. 2003. Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Am. J. Respir. Crit. Care Med. 167:1341-1347. (Pubitemid 36609717)
6. Weiner M, Benator D, Burman W, Peloquin CA, Khan A, Vernon A, Jones B, Silva-Trigo C, Zhao Z, Hodge T. 2005. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin. Infect. Dis. 40:1481-1491. (Pubitemid 40628637)
7. Srivastava S, Pasipanodya JG, Meek C, Leff R, Gumbo T. 2011. Multidrug-resistant tuberculosis not due to noncompliance but to betweenpatient pharmacokinetic variability. J. Infect. Dis. 204:1951-1959.
8. Chideya S, Winston CA, Peloquin CA, Bradford WZ, Hopewell PC, Wells CD, Reingold AL, Kenyon TA, Moeti TL, Tappero JW. 2009. Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. Clin. Infect. Dis. 48:1685-1694.
9. Egelund EF, Peloquin CA. 2012. Pharmacokinetic variability and tuberculosis treatment outcomes, including acquired drug resistance. Clin. Infect. Dis. 55:178-179.
10. Pasipanodya JG, Srivastava S, Gumbo T. 2012. Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clin. Infect. Dis. 55:169-177.
11. WHO. 2012. Global tuberculosis control: WHO report 2012. World Health Organization, Geneva, Switzerland.
12. McIlleron H, Wash P, Burger A, Norman J, Folb PI, Smith P. 2006. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob. Agents Chemother. 50:1170-1177.
13. Gurumurthy P, Ramachandran G, Hemanth Kumar AK, Rajasekaran S, Padmapriyadarsini C, Swaminathan S, Venkatesan P, Sekar L, Kumar S, Krishnarajasekhar OR, Paramesh P. 2004. Malabsorption of rifampin and isoniazid in HIV-infected patients with and without tuberculosis. Clin. Infect. Dis. 38:280-283. (Pubitemid 38113038)
14. Sahai J, Gallicano K, Swick L, Tailor S, Garber G, Seguin I, Oliveras L, Walker S, Rachlis A, Cameron DW. 1997. Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection. Ann. Intern. Med. 127:289-293. (Pubitemid 27352050)
15. Polasa K, Murthy KJ, Krishnaswamy K. 1984. Rifampicin kinetics in undernutrition. Br. J. Clin. Pharmacol. 17:481-484. (Pubitemid 14055282)
16. Ministry of Health and Social Welfare. 2006. Manual of the National Tuberculosis and Leprosy Programme in Tanzania, 5th ed. Ministry of Health and Social Welfare, Dar es Salaam, Tanzania
17. WHO. 2012. The international classification of adult underweight, overweight and obesity according to BMI. BMI classification; global database on body mass index. WHO, Geneva, Switzerland. http://apps.who.int/bmi/index.jsp? introPage-intro-3.html. Accessed 5 February 2013.
18. Ruslami R, Nijland HM, Alisjahbana B, Parwati I, van Crevel R, Aarnoutse RE. 2007. Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. Antimicrob. Agents Chemother. 51:2546-2551. (Pubitemid 47047335)
19. Peloquin CA. 2002. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 62:2169-2183. (Pubitemid 35252827)
20. Hutchings A, Routledge PA. 1986. A simple method for determining acetylator phenotype using isoniazid. Br. J. Clin. Pharmacol. 22:343-345. (Pubitemid 17170725)
21. Parkin DP, Vandenplas S, Botha FJ, Vandenplas ML, Seifart HI, van Helden PD, van der Walt BJ, Donald PR, van Jaarsveld PP. 1997. Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis. Am. J. Respir. Crit. Care Med. 155:1717-1722. (Pubitemid 27216683)
22. Seifart HI, Parkin DP, Botha FJ, Donald PR, van der Walt BJ. 2001. Population screening for isoniazid acetylator phenotype. Pharmacoepidemiol. Drug Saf. 10:127-134. (Pubitemid 32590943)
23. Lin MY, Lin SJ, Chan LC, Lu YC. 2010. Impact of food and antacids on the pharmacokinetics of anti-tuberculosis drugs: systematic review and meta-analysis. Int. J. Tuberc. Lung Dis. 14:806-818.
24. Peloquin CA, Namdar R, Dodge AA, Nix DE. 1999. Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids. Int. J. Tuberc. Lung Dis. 3:703-710. (Pubitemid 29378471)
25. Zent C, Smith P. 1995. Study of the effect of concomitant food on the bioavailability of rifampicin, isoniazid and pyrazinamide. Tuber. Lung Dis. 76:109-113.
26. Joshi MV, Saraf YS, Kshirsagar NA, Acharya VN. 1991. Food reduces isoniazid bioavailability in normal volunteers. J. Assoc. Physicians India 39:470-471.
27. Peloquin CA, Namdar R, Singleton MD, Nix DE. 1999. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. Chest 115:12-18. (Pubitemid 29047048)
28. Peloquin CA, Bulpitt AE, Jaresko GS, Jelliffe RW, Childs JM, Nix DE. 1999. Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids. Antimicrob. Agents Chemother. 43:568-572. (Pubitemid 29109520)
29. Peloquin CA, Bulpitt AE, Jaresko GS, Jelliffe RW, James GT, Nix DE. 1998. Pharmacokinetics of pyrazinamide under fasting conditions, with food, and with antacids. Pharmacotherapy. 18:1205-1211. (Pubitemid 28533871)
30. Tappero JW, Bradford WZ, Agerton TB, Hopewell P, Reingold AL, Lockman S, Oyewo A, Talbot EA, Kenyon TA, Moeti TL, Moffat HJ, Peloquin CA. 2005. Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana. Clin. Infect. Dis. 41:461-469. (Pubitemid 41099637)
31. Choudhri SH, Hawken M, Gathua S, Minyiri GO, Watkins W, Sahai J, Sitar DS, Aoki FY, Long R. 1997. Pharmacokinetics of antimycobacterial drugs in patients with tuberculosis, AIDS, and diarrhea. Clin. Infect. Dis. 25:104-111. (Pubitemid 27293083)
32. Hall RG, Leff RD, Gumbo T. 2009. Treatment of active pulmonary tuberculosis in adults: current standards and recent advances. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 29:1468-1481.
33. Narita M, Hisada M, Thimmappa B, Stambaugh J, Ibrahim E, Hollender E, Ashkin D. 2001. Tuberculosis recurrence: multivariate analysis of serum levels of tuberculosis drugs, human immunodeficiency virus status, and other risk factors. Clin. Infect. Dis. 32:515-517. (Pubitemid 32173643)
34. Chang KC, Leung CC, Yew WW, Kam KM, Yip CW, Ma CH, Tam CM, Leung EC, Law WS, Leung WM. 2008. Peak plasma rifampicin level in tuberculosis patients with slow culture conversion. Eur. J. Clin. Microbiol. Infect. Dis. 27:467-472. (Pubitemid 351713064)
35. Aarnoutse RE. 2011. Pharmacogenetics of antituberculosis drugs, p 176-190. In Donald PR, van Helden PD (ed), Antituberculosis chemotherapy. Progress in Respiratory Research, Basel, Switzerland.
36. Ellard GA. 1984. The potential clinical significance of the isoniazid acetylator phenotype in the treatment of pulmonary tuberculosis. Tubercle 65:211-227. (Pubitemid 14027721)